Investor Relations


Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.

Events & Presentations

More events are coming soon.

February 14, 2019 8:00 AM EST
Q4 2018 Incyte Corporation Earnings Conference Call

January 07, 2019 2:00 PM PST
J. P. Morgan 37th Annual Healthcare Conference Q/A Session

January 07, 2019 1:30 PM PST
J. P. Morgan 37th Annual Healthcare Conference Presentation

SEC Filings

Filing date Description Filing Group View

Report of unscheduled material events or corporate event

Current Reports


Registration Statements

Annual report which provides a comprehensive overview of the company for the past year

Annual Filings

Investor Contacts

Michael Booth D.Phil
Vice President, Investor Relations
Phone: 302.498.5914

Lauren Kwiecinski
Senior Director, Investor Relations
Phone: 302.498.6141

P.O. Box 43078
Providence, RI 02940-3078 Phone: 877.272.1536